Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Bioventures Investors
AddedFeb 16, 2024
UpdatedJun 28, 2026
Bioventures Investors

Bioventures Investors

Operating

BioVentures Investors, LLC: A US-based venture capital firm specializing in life sciences and healthcare sectors.

Location
Wellesley, MA, US
Founded
1998
Firm
Compare
Portfolio
Employees
Website

Investments

Georgiamune
Georgiamune

Total Raised

$75M

Rounds

2

Series A$75MAugust 2023
Brainbox Solutions
Brainbox Solutions

Total Raised

$39.5M

Rounds

4

Series A$23MDecember 2020
Sonomotion
Sonomotion

Total Raised

$26.9M

Rounds

3

Series B$10MNovember 2019
Endotronix
Endotronix

Total Raised

$129.6M

Rounds

10

Series D$70MSeptember 2018
Series C$37.1MJuly 2016
Unified Information Devices
Unified Information Devices

Total Raised

$2.5M

Rounds

1

Series Unknown$2.5MJuly 2018
CoNextions Medical
CoNextions Medical

Total Raised

$12.9M

Rounds

7

Series Unknown$2.2MMarch 2017
POC Medical Systems
POC Medical Systems

Total Raised

$22.1M

Rounds

2

Series A$21MJanuary 2017
Cylene Pharmaceuticals
Cylene Pharmaceuticals

Total Raised

$102.3M

Rounds

6

Series D$12MSeptember 2010
Series C$44MJanuary 2007
Series B$26.3MMay 2005
Hydrocision
Hydrocision

Total Raised

$33.8M

Rounds

8

Series UnknownSeptember 2010
Hydra Biosciences
Hydra Biosciences
Acquired

Total Raised

$94.9M

Rounds

6

Series D$22MJanuary 2009
Series C$34MMarch 2008
Series B$18.9MJanuary 2004
Biolex Therapeutics
Biolex Therapeutics
Public

Total Raised

$196.7M

Rounds

9

Series D$60MOctober 2008
Verax Biomedical
Verax Biomedical

Total Raised

$64.8M

Rounds

11

Series E$2.5MDecember 2007
Series Unknown$3MJune 2007
Series B$15MOctober 2005
Series A$4.5MJuly 2003
Series A$4.5MMay 2002
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Public

Total Raised

$84.6M

Rounds

9

Series Unknown$20MAugust 2004
Series A$12MJanuary 2004